Pembrolizumab/Finotonlimab is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include Fudan University (1) and Ji Dongmei (1). Registered phases: Phase 2 and Phase 3. Conditions studied include Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation; Advanced PDTC or ATC With NRAS Mutation; Squamous Cell Carcinoma of Head and Neck.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06970353 | Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer (ClinicalTrials.gov ↗) Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation, Advanced PDTC or ATC With NRAS Mutation |
Phase 2 | Recruiting |
| NCT07509099 | Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC (ClinicalTrials.gov ↗) Squamous Cell Carcinoma of Head and Neck |
Phase 3 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation | 1 |
| Advanced PDTC or ATC With NRAS Mutation | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Lead sponsor | Trials |
|---|---|
| Fudan University | 1 |
| Ji Dongmei | 1 |
| Register | Pembrolizumab/Finotonlimab trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pembrolizumab/Finotonlimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pembrolizumab/Finotonlimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.